Ad hoc announcement pursuant to Art. 53LR
- All Board proposals approved by Shareholders
Allschwil, Switzerland – April 142022
At the annual general meeting (AGM) of Idorsia SA (SIX: IDIA) held today in Allschwil, Switzerland, shareholders voted in favor of all the proposals of the board of directors at a large majority.
The meeting was held in accordance with the requirements of the COVID‑19 Ordinance 3, issued by the Swiss Federal Council. As a result, attendance in person was not possible and voting took place by independent proxy. A total of 5,474 shareholders voted by independent proxy, representing a total of 111,093,671 shares, or 62.78% of the total shares outstanding.
Matthew Simon, MD, Chairman of the Board of Idorsia, said:
“My thanks go to our shareholders, who have once again shown their support for Idorsia’s value creation strategy, by fully approving all the items on the agenda of the General Meeting. With our first product launches imminent, Idorsia is poised to transform into a full-fledged biopharmaceutical company that can take innovation from the lab to the bedside. We will also see important results from the clinical pipeline this year, so be prepared for more!
The shareholders approved the 2021 annual report, as well as the statutory and consolidated financial statements for 2021. The shareholders also approved the 2021 remuneration report by way of an advisory vote.
The shareholders approved the aggregate maximum remuneration of the board of directors (non-executive directors) for the term of office until the annual general meeting 2023 and the aggregate maximum amount of the remuneration of the executive committee of Idorsia (CEI) for the 2023 financial year.
The shareholders discharged all members of the Board of Directors and Executive Management for the 2021 financial year.
Shareholders approved a conditional share capital increase, providing the flexibility to grant long-term employee incentives focused on creating long-term value in alignment with shareholder interests. The increase in conditional share capital is also necessary to fully cover convertible debt securities, bonds, loans and other similar financing already issued.
Shareholders re-elected all members of the Board of Directors for a term until the close of the 2023 Annual General Meeting. In addition, shareholders re-elected Mathieu Simon as Chairman of the Board of Directors and Mathieu Simon, Felix R. Ehrat and Srishti Gupta as members. of the compensation committee.
At the end of the General Assembly, the Idorsia Board of Directors is composed of a total of 7 members: Mathieu Simon (Chairman), Jean-Paul Clozel, Joern Aldag, Felix R. Ehrat, Sandy Mahatme, Peter Kellogg and Srishti Gupta.
BachmannPartner AG was re-elected as an independent proxy for a term until the end of the 2023 AGM.
Ernst & Young AG, Basel, has been re-elected auditor for the 2022 financial year.
Notes to Editor
Idorsia Ltd seeks more – We have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company with a strong scientific core.
Based near Basel, Switzerland – a European biotechnology hub – Idorsia specializes in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals spanning all disciplines from laboratory to bedside, state-of-the-art facilities and a strong track record – the constellation ideal for translating R&D efforts into commercial success.
Idorsia was listed on the SIX Swiss Exchange (stock symbol: IDIA) in June 2017 and has over 1,200 highly qualified specialists dedicated to achieving our ambitious goals.
For more information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications
Idorsia Pharmaceuticals AG, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
[email protected] – [email protected] – www.idorsia.com
The above information contains certain “forward-looking statements”, relating to the Company’s business, which can be identified by the use of forward-looking terms such as “estimates”, “believes”, “expects”, “may”. , “is expected”, “will”, “will”, “will”, “should”, “would”, “seek”, “wait”, “anticipate” or similar expressions, or through discussions of strategy, plans or the intentions. These statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company, and anticipated customer demand for such products. and products from the company’s existing portfolio. These statements reflect the company’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, estimated or expected.